期刊
BIOMEDICINE & PHARMACOTHERAPY
卷 137, 期 -, 页码 -出版社
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.biopha.2021.111381
关键词
Lung cancer; Traditional Chinese medicine; Adjuvant therapy; Immunotherapy
资金
- key special subprojects of the National Key Research and Development Program [2017YFC1308704]
- National Natural Science Foundation of China [81760554]
With continuous breakthroughs in molecular biology and biochemistry, significant progress has been made in the treatment of lung cancer, particularly with standard treatments improving patient prognosis and immunotherapy providing positive outcomes. In contrast, traditional Chinese medicine has limited research in the field of lung cancer, but has shown progress in non-small cell lung cancer.
With the continuous breakthroughs in molecular biology and biochemistry, we have constantly made great progress in the treatment of lung cancer. There is no doubt that standard treatment (such as surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy) has greatly improved the prognosis of lung cancer populations. In particular, the immunotherapy has brought more and more good news to countless lung cancer patients. In contrast to these standard treatments, traditional Chinese medicine (TCM) rarely has a profound and comprehensive overview in the field of lung cancer. This article will summarize the latest progress of TCM in lung cancer which is mainly non-small cell lung cancer (NSCLC) from theory to clinical practice, which would carry forward the sophisticated TCM and promote the development of modern medicine.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据